Published by Josh White on 24th February 2026
(Sharecast News) - Avacta Therapeutics said on Tuesday that new preclinical analysis indicated its proprietary 'preCISION' tumour-activated delivery platform could offer pharmacokinetic advantages over the marketed antibody drug conjugate Enhertu, as it prepared to begin a phase one trial of its lead programme AVA6103 in the first quarter of 2026.